E. Yvonne Jones

University of Oxford — United Kingdom

Immunology and Microbiology · Life Sciences

105h-index31.9kcitations531works6.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(83), T-cell and B-cell Immunology(80), Axon Guidance and Neuronal Signaling(57), Glycosylation and Glycoproteins Research(56), Immunotherapy and Immune Responses(51)

Publications526 total

Longitudinal analysis of neutralizing antibodies against SARS-CoV-1 and different SARS-CoV-2 strains in breakthrough and unvaccinated COVID-19 patients in Thailand (2021-2022)
Scientific Reports·2026Open Access
856 Masking the activity of a potent cytokine mimic via site specific chemical modification
Regular and Young Investigator Award Abstracts·2025Open Access
Enhancing the development of Cherenkov Telescope Array control software with Large Language Models
2025Open Access
Enhancing the development of Cherenkov Telescope Array control software with Large Language Models
arXiv (Cornell University)·2025Open Access
Health Status And Delays In Referral-To-Treatment Waiting Times for Elective Admissions of Adults From Deprived Areas And Ethnic Minority Backgrounds: A Study of Healthcare Inequalities
Journal of Racial and Ethnic Health Disparities·2025· 3 citedOpen Access
881-P: BCG Clinical Trial Programs in Advanced Type 1 Diabetes—2025 Update
Diabetes·2025
Evaluation of mediators of seasonal variation in fatal strokes: a multicentre registry‐based cohort study
Journal of Stroke and Cerebrovascular Diseases·2025· 1 citedOpen Access
Conditional Activation of Protein Therapeutics by Templated Removal of Peptide Nucleic Acid Masking Groups
Angewandte Chemie·2025Open Access
Structural insights into Frizzled3 through nanobody modulators
Nature Communications·2024· 11 citedOpen Access
Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers
BMC Infectious Diseases·2024· 7 citedOpen Access
Improving the representativeness of UK’s national COVID-19 Infection Survey through spatio-temporal regression and post-stratification
Nature Communications·2024· 7 citedOpen Access
Cachd1 interacts with Wnt receptors and regulates neuronal asymmetry in the zebrafish brain
Science·2024· 13 citedOpen Access
Publisher Correction: Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells
Nature Communications·2024· 3 citedOpen Access
Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells
Nature Communications·2024· 22 citedOpen Access
Southeast Asia initiative to combat SARS-CoV-2 variants (SEACOVARIANTS) consortium
Wellcome Open Research·2024Open Access
Structure and function of Semaphorin-5A glycosaminoglycan interactions
Nature Communications·2024· 18 citedOpen Access
Determining sex-driven excitation-contraction coupling mechanisms in young populations
Biophysical Journal·2024
Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study
Journal of Epidemiology & Community Health·2023· 25 citedOpen Access
Experimental phasing opportunities for macromolecular crystallography at very long wavelengths
Communications Chemistry·2023· 20 citedOpen Access
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
Nature Communications·2023· 32 citedOpen Access
page 1 of 27Next →

Frequent Co-authors

David I. Stuart(22), Karl Harlos(10), A.R. Aricescu(7), Robert Esnouf(7), Christian Siebold(7), John I. Bell(6), Vincenzo Cerundolo(6), D.K. Stammers(5), Andrew J. McMichael(5), Gavin Screaton(5), P. Anton van der Merwe(4), Jingshan Ren(4), Carl Ross(4), Michael Koch(4), Simon J. Davis(4), Robert J.C. Gilbert(4), Jonathan M. Grimes(4), Lars Fugger(3), Véronique M. Braud(3), Benjamin E. Willcox(3)